Prevention of human diseases has become a major focus of biomedical investigators
around the world. Our current screening and treatment regimens for colorectal cancer are …

Abstract Higher cyclooxygenase 2 (COX-2) expression is often observed in aggressive
colorectal cancers (CRCs). Here, we attempt to examine the association between COX-2 …

Non‐steroidal anti‐inflammatory drugs are chemopreventive for colorectal cancer. This
effect is due in part to their ability to inhibit the inducible isoform of cyclooxygenase (COX‐2) …

Regular administration of non‐steroidal anti‐inflammatory drugs (NSAIDs) may reduce the
incidence of colorectal cancer by targeting cyclo‐oxygenase‐2 (Cox‐2), a key enzyme in …

Publisher Summary Cyclooxygenase, prostaglandin synthase, is expressed in mammalian
cells as two distinct isosymes that show about 60% amino acid sequence identity. The two …

The rate-limiting enzyme in arachidonate metabolism is mediated by enzymes known as
cyclooxygenases (COXs). These enzymes catalyze the biosynthesis of prostaglandin H 2 …

Background & Aims: Cyclooxygenase (COX) enzymes catalyze the conversion of
arachidonic acid to prostaglandins. Evidence suggests that nonsteroidal anti-inflammatory …

Cyclooxygenase (COX)-2 levels are elevated in several types of human cancer tissues.
Nonselective nonsteroidal anti-inflammatory drugs (NSAIDs) inhibit both the COX-1 and …

For more than a century, inhibition of prostaglandin biosynthesis via inhibition of the fatty
acid cyclooxygenase (COX) has been achieved by non-steroidal anti-inflammatory drugs …

Recent epidemiologic studies have shown a 40–50% reduction in mortality from colorectal
cancer in individuals who take nonsteroidal antiinflammatory drugs on a regular basis …